title: Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status.
abstract: BACKGROUND
  The antiparkinsonian drug L-dopa causes increased cellular synthesis of homocysteine and consequent hyperhomocysteinemia in rats. This effect of L-dopa on plasma homocysteine is accentuated under conditions of impaired homocysteine metabolism such as folate deficiency.
  
  
  OBJECTIVE
  To investigate the effect of L-dopa administration and B-vitamin status on plasma homocysteine concentrations in humans with PD.
  
  
  METHODS
  Plasma homocysteine, folate, vitamin B(12), and pyridoxal-5'-phosphate (PLP) concentrations were determined in 40 individuals diagnosed with idiopathic PD who were being treated as outpatients at the Boston University Medical Center Neurology Clinic. Twenty of the patients were on L-dopa therapy (treatment group) and 20 were L-dopa-naive (control group).
  
  
  RESULTS
  The mean plasma homocysteine concentration was higher in the treatment group than in the controls (p = 0.018). Plasma homocysteine was correlated with plasma folate, vitamin B(12), and PLP concentrations in the treatment group (p <or= 0.007) but not in the controls.
  
  
  CONCLUSIONS
  L-Dopa can cause hyperhomocysteinemia in PD patients, the extent of which is influenced by B-vitamin status. The B-vitamin requirements necessary to maintain normal plasma homocysteine concentrations are higher in L-dopa-treated patients than in those not on L-dopa therapy. B-Vitamin supplements may be warranted for PD patients on L-dopa therapy.
authors.affiliation: Vitamin Bioavailability Lab, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA, USA. jwmiller@ucdavis.edu
authors.forename: J W
authors.initials: JW
authors.lastname: Miller
authors.forename: J
authors.initials: J
authors.lastname: Selhub
authors.forename: M R
authors.initials: MR
authors.lastname: Nadeau
authors.forename: C A
authors.initials: CA
authors.lastname: Thomas
authors.forename: R G
authors.initials: RG
authors.lastname: Feldman
authors.forename: P A
authors.initials: PA
authors.lastname: Wolf
mesh_terms: D000978:Antiparkinson Agents / Q000627:therapeutic use; D005260:Female; D005492:Folic Acid / Q000097:blood; D006710:Homocysteine / Q000097:blood*; D006801:Humans; D020138:Hyperhomocysteinemia / Q000097:blood / Q000139:chemically induced*; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use*; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000097:blood* / Q000188:drug therapy; D011732:Pyridoxal Phosphate / Q000097:blood; D012307:Risk Factors; D014805:Vitamin B 12 / Q000097:blood; D014803:Vitamin B Complex / Q000097:blood*
chemical_list: D000978:Antiparkinson Agents; D006710:Homocysteine; D014803:Vitamin B Complex; D007980:Levodopa; D011732:Pyridoxal Phosphate; D005492:Folic Acid; D014805:Vitamin B 12